{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:49:22Z","timestamp":1786121362391,"version":"build-2736575974"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82500502"],"award-info":[{"award-number":["82500502"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In multiple countries, clinical guidelines recommend proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors for lowering low-density lipoprotein cholesterol (LDL-C) in individuals with atherosclerotic cardiovascular disease (ASCVD). Comprehensive comparisons of the efficacy, safety, and cost-effectiveness across different PCSK9 inhibitors remain limited, and current evidence requires updating. To address this gap, this study applies a health technology assessment framework to systematically evaluate the use of PCSK9 inhibitors in patients with ASCVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, EMBASE, and the Cochrane Library was conducted from database inception to February 28, 2026 to identify randomized controlled trials (RCTs) comparing PCSK9 inhibitors with standard care (statins with or without ezetimibe) in patients with ASCVD. Both pairwise and network meta-analyses were applied to synthesize direct and indirect evidence. Trial sequential analysis (TSA) was performed to evaluate the sufficiency of the accumulated data. In addition, a Markov model was developed from the perspective of the Chinese healthcare system to assess the cost-effectiveness of PCSK9 inhibitors in ASCVD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 24 RCTs comprising 63,328 participants were included. The results of TSA and network meta-analysis showed that, compared with SOC, all three PCSK9 inhibitors significantly reduced LDL-C levels. No statistically significant differences were found for stroke outcomes. However, both alirocumab and evolocumab significantly reduced the risk of non-fatal myocardial infarction. None of the three PCSK9 inhibitors was associated with an increased risk of serious adverse events. Using the meta-analysis findings and data from the Chinese healthcare system, the incremental cost-effectiveness ratios (ICERs) for alirocumab, evolocumab, and inclisiran versus standard care were estimated at USD 12,791.07\/QALY, USD 11,646.38\/QALY, and USD 31,730.14\/QALY, respectively. In a scenario analysis incorporating a 72.1% reduction in the price of inclisiran, its ICER decreased to USD 9,686.31\/QALY. The one-way sensitivity analysis showed that the discount rate exerted the greatest influence on model outcomes. In the price-reduction scenario, probabilistic sensitivity analysis indicated that inclisiran had a 96.6% probability of being cost-effective at a willingness-to-pay threshold of USD 13,410\/QALY.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Currently, evolocumab demonstrates relative advantages in lipid-lowering efficacy, cardiovascular outcomes, and economic value for patients with ASCVD. Alirocumab represented a cost-effective alternative. In the scenario analysis incorporating a 72.1% reduction in the price of inclisiran, inclisiran became a potentially highly cost-effective option in the Chinese healthcare setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1853767","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:21:45Z","timestamp":1786076505000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PCSK9 inhibitors for lipid-lowering treatment in patients with atherosclerotic cardiovascular disease: a health technology assessment"],"prefix":"10.3389","volume":"13","author":[{"given":"Jingjing","family":"Lan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaijia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990\u20132023","volume":"86","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1612921","DOI":"10.3389\/fphar.2025.1612921","article-title":"The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis","volume":"16","author":"Tang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","article-title":"Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease","volume":"2","author":"Fonarow","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology solution set oversight committee","volume":"80","author":"Writing Committee","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","article-title":"2023 Chinese guideline for lipid management","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"988576","DOI":"10.3389\/fcvm.2022.988576","article-title":"Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe","volume":"9","author":"Cheng","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12933-020-01164-8","article-title":"Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics","volume":"19","author":"Morieri","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"106442","DOI":"10.1016\/j.ejim.2025.106442","article-title":"Optimizing PCSK9 inhibitor therapy: understanding and managing suboptimal LDL-C response in clinical practice","volume":"140","author":"Di Girolamo","year":"2025","journal-title":"Eur J Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","article-title":"An \u201cinclisiran first\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease","volume":"83","author":"Koren","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"108812","DOI":"10.1016\/j.pharmthera.2025.108812","article-title":"Therapeutic PCSK9 targeting: inside versus outside the hepatocyte?","volume":"268","author":"Corsini","year":"2025","journal-title":"Pharmacol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1016\/j.jacc.2017.10.001","article-title":"PCSK9 Inhibitors: economics and policy","volume":"70","author":"Hlatky","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"648244","DOI":"10.3389\/fphar.2021.648244","article-title":"Cost-effectiveness of alirocumab for the secondary prevention of cardiovascular events after myocardial infarction in the Chinese setting","volume":"12","author":"Liang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2020.09.021","article-title":"Estimation of the major cardiovascular events prevention with inclisiran","volume":"313","author":"Cordero","year":"2020","journal-title":"Atherosclerosis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1017\/S0266462323000296","article-title":"Cost-effectiveness of adding ezetimibe and\/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults","volume":"39","author":"Xiang","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"","journal-title":"Eur Heart J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"B27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.diabet.2017.01.004","article-title":"Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: rationale and design of the ODYSSEY DM-INSULIN trial","volume":"43","author":"Cariou","year":"2017","journal-title":"Diabetes Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1536\/ihj.22-052","article-title":"Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome","volume":"63","author":"Hao","year":"2022","journal-title":"Int Heart J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e888","DOI":"10.4244\/EIJ-D-22-00735","article-title":"Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial","volume":"18","author":"Mehta","year":"2022","journal-title":"EuroIntervention"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2022.01.058","article-title":"The trajectory of lipoprotein(a) during the peri- and early postinfarction period and the impact of proprotein convertase subtilisin\/kexin type 9 inhibition","volume":"171","author":"Vavuranakis","year":"2022","journal-title":"Am J Cardiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O'Donoghue","year":"2022","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5937\/jomb0-54773","article-title":"Pcsk9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome","volume":"44","author":"Wang","year":"2025","journal-title":"J Med Biochem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40263-024-01145-5","article-title":"Adjunctive PCSK9 inhibitor evolocumab in the prevention of early neurological deterioration in non-cardiogenic acute ischemic stroke: a multicenter, prospective, randomized, open-label, clinical trial","volume":"39","author":"Tian","year":"2025","journal-title":"CNS Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jjcc.2025.04.002","article-title":"Effect of PCSK9 inhibitor usage on coronary endothelial dysfunction in patients with hypercholesterolemia after coronary stenting: the CuVIC-2 trial","volume":"86","author":"Akiyama","year":"2025","journal-title":"J Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"oeae055","DOI":"10.1093\/ehjopen\/oeae055","article-title":"Early and short-term use of proprotein convertase anti-subtilisin-kexin type 9 inhibitors on coronary plaque stability in acute coronary syndrome","volume":"4","author":"Uehara","year":"2024","journal-title":"Eur Heart J Open"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jacasi.2023.09.006","article-title":"Efficacy and safety of inclisiran in Asian patients: results from ORION-18","volume":"4","author":"Huo","year":"2024","journal-title":"JACC Asia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"117471","DOI":"10.1016\/j.atherosclerosis.2024.117471","article-title":"Effect of combining evolocumab with statin on carotid intraplaque neovascularization in patients with premature coronary artery disease (EPOCH)","volume":"391","author":"Han","year":"2024","journal-title":"Atherosclerosis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: from basic science discoveries to clinical trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-022-01542-4","article-title":"PCSK9 Inhibitors for secondary prevention in patients with cardiovascular diseases: a Bayesian network meta-analysis","volume":"21","author":"Wang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40256-025-00778-1","article-title":"Efficacy of PCSK9 inhibitors on clinical outcomes in patients with established atherosclerotic cardiovascular disease: a network meta-analysis","volume":"26","author":"Raone","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"B43","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40258-025-00971-y","article-title":"Cost-effectiveness analysis of evolocumab or inclisiran in combination with statins versus statin monotherapy among patients with ASCVD in China","volume":"23","author":"Wang","year":"2025","journal-title":"Appl Health Econ Health Policy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1415668","DOI":"10.3389\/fcvm.2024.1415668","article-title":"Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis","volume":"11","author":"Jiang","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1454918","DOI":"10.3389\/fcvm.2024.1454918","article-title":"The efficacy and safety of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis","volume":"11","author":"Liu","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1708701","DOI":"10.3389\/fphar.2025.1708701","article-title":"Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective","volume":"16","author":"Hu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1080\/13696998.2025.2575456","article-title":"Cost-effectiveness of non-statin lipid-lowering therapies as an add-on to statins for achieving low-density lipoprotein cholesterol therapeutic targets in very high-risk patients in the Spanish setting","volume":"28","author":"Climente-Mart\u00ed","year":"2025","journal-title":"J Med Econ"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1853767\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:21:46Z","timestamp":1786076506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1853767\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":47,"alternative-id":["10.3389\/fcvm.2026.1853767"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1853767","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"article-number":"1853767"}}